Contributed by Marsha I. Lester, March 10, 2020 (sent for review October 1, 2019; reviewed by Keith Kuwata and A. R. Ravishankara) Reaction scheme illustrating the generation of MVK-oxide + ...

Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada Life Sciences Division, TRIUMF, 4004 Wesbrook ...

and Lutetium-177 (Lu-177) – at Ontario Power Generation's (OPG) Darlington Nuclear Generating Station. The Canadian Nuclear Safety Commission has approved a licence amendment that allows OPG ...

Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable ...

ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant ...

Small cell lung cancer (SCLC), accounting for 10–20% of lung cancers, remains one of the most aggressive neuroendocrine malignancies, with fewer than 7% of patients surviving beyond five years. While ...

Under the terms of the agreement, Radiopharm will use ITM’s n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 ...

Radiopharm secures lutetium-177 supply agreement View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks PSEi Composite ...